Clinical trial
Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer
NCT06731413 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer
- Lead sponsor
- Virginia Commonwealth University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 11, 2025
- Completion date
- July 30, 2033
- Enrollment
- 40 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
advanced non-small cell lung cancer, metastatic non small cell lung cancer, non-small cell lung cancer, nsclc